CorMedix Inc. (NASDAQ:CRMD) director Myron Kaplan has disclosed an open-market purchase of 25,000 shares of the company's common stock, according to a regulatory filing. The transaction, executed on November 16, 2026, carried a total value of $122,000, with per-share prices ranging from $4.87 to $4.88.
The timing of the acquisition places the insider buy in close proximity to the stock's 52-week low of $4.49. Shares of CorMedix had declined 7% over the week leading up to the disclosure, a move that coincided with the director's purchase. The buy also comes as the stock was recently changing hands at $4.50, down 3.64% in the session.
Following the transaction, Kaplan directly holds 256,487 shares of CorMedix common stock. In addition to his direct stake, the filing indicates that 20,000 shares are held indirectly by his spouse, and a further 10,000 shares are held by his spouse as guardian for grandchildren. Kaplan disclaims beneficial ownership of these indirectly held securities.
Recent Financial Results
The insider transaction follows the company's third-quarter earnings report, which presented a mixed picture. CorMedix recorded revenue of $54.5 million, surpassing Wall Street expectations by 2.31%. However, the company reported a net loss of $0.19 per share, wider than the $0.10 loss analysts had projected. According to the report, the wider loss is attributed to adjustments in the reimbursement setting for its main product, DefenCath.
The revenue beat and the larger-than-expected loss illustrate the company's current financial landscape, where top-line performance exceeded consensus but bottom-line results were pressured by reimbursement-related factors tied to its primary product.
Analyst Adjustments
In a separate development, Oppenheimer has revised its valuation model for CorMedix, lowering its price target to $13 from $15 while maintaining an Outperform rating on the shares. The adjustment follows the removal of TPN from Oppenheimer's model and the inclusion of Heron, which adds commercial revenue and leverages existing infrastructure, according to the report.
The revised price target and the maintained Outperform rating reflect the analyst's updated view of the company's commercial outlook, incorporating the changes to the model. The report did not provide further detail on the specific assumptions behind the revision.
Valuation Context
According to InvestingPro analysis cited in the report, CRMD appears undervalued with a Fair Value of $6.71, placing it among undervalued stocks worth monitoring. The company trades at a P/E ratio of just 6.25 despite analyst expectations for continued profitability. The report did not elaborate on the methodology behind the Fair Value estimate or the specific basis for the profitability expectations.
The combination of an insider purchase near the 52-week low, a revenue beat with a wider net loss, and a lowered but still positive analyst price target presents a complex picture for investors evaluating the stock. The report did not indicate whether the director's purchase was part of a pre-arranged plan or discretionary, and it did not provide further context on the director's historical trading activity.